Regulatory Compliance

Austin – October 02, 2026 -- Oracle has committed to subscribing to a portion of electricity generated by the Point Beach Nuclear Plant in Wisconsin, a move expected to save utility customers approximately $300 million in fuel costs. The commitment is designed to shield more than 1 million Wisconsin utility customers from the plant's rising operating costs while preserving carbon-free baseload power for the state grid.

Oracle absorbs rising nuclear fuel costs to protect household electricity bills

Point Beach has supplied dependable, carbon-free power to Wisconsin for more than 50 years. By subscribing to a share of the plant's output, Oracle intends to cover increases in fuel costs that would otherwise be passed on to ratepayers, according to Mahesh Thiagarajan, executive vice president of Oracle Cloud Infrastructure.

South San Francisco, Calif. – October 02, 2026 -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) has granted 35,275 restricted stock units to 18 non-executive employees under its Inducement Plan.

Rigel ties new hire equity to four-year vesting schedule

The restricted stock units vest over four years, with 25% of each grant releasing annually. The Compensation Committee of Rigel's Board of Directors approved the awards as an inducement material to new employees joining the company.

Grants comply with Nasdaq Listing Rule 5635(c)(4)

Rigel issued the awards in accordance with Nasdaq Listing Rule 5635(c)(4), which permits companies to grant equity inducements to new employees outside shareholder-approved equity plans. The rule requires public disclosure of such grants, which Rigel has now made.

Burgettstown, Pa. – October 02, 2026 -- 6K Additive Inc. (ASX: 6KA) has executed a final US$27.4 million loan agreement with the Export-Import Bank of the United States (EXIM) to fund expansion of its critical materials manufacturing plant in Burgettstown, Pennsylvania.

EXIM finalizes largest Make More in America loan for advanced materials

The facility, approved by EXIM's board on December 4, 2025, is the first deal structured in coordination with the U.S. Department of War's Defense Production Act Title III initiative and the largest loan issued under EXIM's Make More in America Initiative (MMIA) for advanced materials and manufacturing to date.

Santa Cruz, Calif. – October 02, 2026 -- Emboline, Inc. completed the first commercial use of its Emboliner® Embolic Protection System in the United States on October 1, 2026, just weeks after receiving U.S. Food and Drug Administration 510(k) clearance.

Two TAVR procedures mark Emboline's commercial debut

The device was deployed during two transcatheter aortic valve implantation (TAVR) procedures performed by Tamim Nazif, MD, Co-Director of the Structural Heart and Valve Center at New York-Presbyterian/Columbia University Irving Medical Center. Dr. Nazif also serves as Co-Principal Investigator of the PROTECT H2H clinical trial, which evaluated the Emboliner's performance ahead of regulatory approval.

Vancouver – October 02, 2026 -- Trilogy Metals Inc. (NYSE American: TMQ; TSX: TMQ) closed a $17.8 million strategic equity investment from the United States Department of War (DOW) on September 11, 2026, as part of a broader $35.6 million financing package tied to its Upper Kobuk Mineral Projects (UKMP) in Alaska. The company reported a cash balance of $31.2 million and adjusted working capital of $30.3 million as of August 31, 2026, which it says substantially funds its share of Ambler Metals LLC's fiscal 2026 budget.

Kilmarnock – October 02, 2026 -- Copenhagen Infrastructure Partners (CIP) has taken a Financial Investment Decision for Kilmarnock South, a 350 MW/1,400 MWh lithium-ion battery energy storage system in south Ayrshire, Scotland, committing over EUR 270 million (GBP 232 million) through its fourth flagship fund, Copenhagen Infrastructure IV.

Construction begins with commercial operations targeted for Q1 2028

Kilmarnock South is now under construction and is scheduled to reach commercial operations in the first quarter of 2028. At four hours of duration, it will become the longest-duration asset in CIP's UK storage portfolio once operational, designed to store surplus Scottish wind power and release it to the grid during periods of network capacity.

Stockholm – October 02, 2026 -- Autoliv, Inc. (NYSE: ALV; SSE: ALIVsdb) has appointed Natalie Draisin and Thomas Manfred Müller to its Research Advisory Board, expanding a panel of external experts that guides the automotive safety supplier's long-term research agenda.

Autoliv broadens external expertise with public health and automotive industry veterans

Natalie Draisin serves as Director of the North American Office and United Nations Representative at FIA Foundation and is an External Affiliate at Johns Hopkins Bloomberg School of Public Health. Thomas Manfred Müller, PhD, is a board member, advisor and business angel with executive experience at Audi, BMW, Volvo Cars, and Volkswagen Group.

Seoul – October 02, 2026 -- AUTOCRYPT has established a Public Key Infrastructure (PKI) system for Plug&Charge (PnC) services in South Korea, validated across electric vehicles from six global automotive brands.

Six automakers validate shared authentication framework

The PKI infrastructure was tested on vehicles from Hyundai Motor, Kia, KG Mobility, BMW, Mercedes-Benz and Tesla, enabling these brands to connect to charging point operators (CPOs) through a single authentication system rather than separate proprietary frameworks.

Milan – October 02, 2026 -- Hansoh Pharma's dual-biased GLP-1/GIP receptor agonist Olatorepatide (HS-20094) achieved a mean weight loss of 19.3% at Week 48 in the 15 mg dose group of a Phase III Chinese trial, with no plateau observed in the weight-loss curve.

The data, presented as a Late-breaking Abstract oral presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting running September 28 to October 2, 2026 in Milan, come from the LIGHTEN study, a multicenter, randomized, double-blind, placebo-controlled trial enrolling 604 Chinese adults with overweight or obesity.

Trial enrolled 604 participants across four dose arms over 48 weeks

Participants with a BMI of 28 kg/m2 or above, or 24-28 kg/m2 with a weight-related comorbidity, were randomized 1:1:1:1 to once-weekly subcutaneous Olatorepatide at 5mg, 10mg or 15mg, or placebo. A total of 90.1% completed the full 48-week treatment period.

St. Louis – October 02, 2026 -- DOOR (OTC: LTCH) has finalized a settlement with the U.S. Securities and Exchange Commission, closing a four-year investigation into legacy revenue recognition and key performance indicator practices with a $1.0 million civil penalty payable in quarterly installments.

SEC closes investigation that began in 2022

The SEC approved the previously disclosed settlement, which the Company first announced in principle on October 02, 2026. DOOR consented to an administrative order without admitting or denying the regulator's findings.

Company filed seven years of restated financial statements

Since late 2024, DOOR has filed seven years of financial statements, including restated prior periods, becoming current with its SEC reporting obligations in February 2026 for the first time since mid-2022.